Impact Of Minimal Residual Disease (Mrd) Status In Clinical Outcomes Of Patients With Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (All) Treated With Inotuzumab Ozogamicin (Ino) In The Phase 3 Ino-Vate Trial.
JOURNAL OF CLINICAL ONCOLOGY（2018）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要